Viewing Company Celgene Corp | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Celgene Corp Stock Symbol: CELG-Q

Last Price Recorded: $121.3300 on 2017-10-20

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2017-10-20 BUY William Chin

This is revisiting old highs, which is a very bullish sign. In this case, it actually broke above its old highs. The current correction seems very healthy as long as it continues making higher lows. Add to your position, but keep a Stop at around $110.


Price:
$121.330
Subject:
TECHNICAL ANALYSIS & MACRO STRATEGY
Bias:
UNKNOWN
Owned:
Unknown
2017-09-20 PAST TOP PICK Bruce Murray

(A Top Pick Oct 4/16. Up 38%.) One of the outstanding growth stocks in the US medical field. They have a plethora of new drugs coming out. Sales are growing at about 25% per annum. With the current earnings, the target price could move into the $165-$170 due to the growth rate. The company is more likely to surprise on the upside and another $1 of earnings could give you a $20-$25 a share. This could be a $200 stock. Still a Buy.


Price:
$144.240
Subject:
NORTH AMERICAN
Bias:
BULLISH
Owned:
Yes
2017-09-19 TOP PICK Gordon Reid

This has done extremely well. It is growing quickly. Has a good pipeline with 4 drugs that he believes could be $1 billion or more in revenue. The biggest property they own is Revlimid. They concentrate on cancer treating drugs. Not inexpensive, but is reasonably priced. Thinks that next year they will do $8 a share in earnings, less than 20X, and growing at a rapid rate. (Analysts’ price target is $156.)


Price:
$143.470
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-09-14 PAST TOP PICK Paul Macdonald

(Top Pick Feb 22/17, Up 19%).  They have a blood cancer drug.  They are testing it on all kinds of other indications.  They have the ability to double the revenues based on their existing products.  It is the more growthy component of his portfolio.


Price:
$140.610
Subject:
HEALTHCARE
Bias:
SELECTIVE
Owned:
Yes
2017-08-09 COMMENT Cameron Hurst

This is big and is more diversified than others, so you are not buying a binary outcome stock. He likes biotech, but would approach it from the equal weight standpoint by going through the SPDR S&P Biotech ETF (XBI-N). Celgene is a good name.


Price:
$135.570
Subject:
US EQUITIES
Bias:
BEARISH on CANADIAN MARKET
Owned:
Unknown
2017-08-01 PAST TOP PICK Bruce Murray

(A Top Pick Oct 4/16. Up 28.79%.) Still loves this and has a target price of about $160 2-3 years out. It has some great products and has a whole plethora of new products before the FDA.


Price:
$135.180
Subject:
NORTH AMERICAN
Bias:
BULLISH on US MARKET
Owned:
Yes
2017-07-31 COMMENT Brooke Thackray

Biotech stocks do really well this time of year from June 23 until September 13. Since 2002 they have been positive 88% of the time, and outperformed the S&P 500 88% of the time. July tends to be the best month for biotech stocks. The chart shows higher lows and a little bit of a break out. From a technical standpoint, this is positive. Very often, he will sell his biotech stocks later on in August.


Price:
$135.410
Subject:
TECHNICAL ANALYSIS & SEASONAL INVESTING
Bias:
CAUTIOUS
Owned:
Unknown
2017-07-25 PAST TOP PICK John O'Connell, CFA

(A Top Pick July 6/16. Up 31.77%.) This is still a Buy. It has cancer drugs that work. Very, very profitable. Amazing balance sheet. Very, very strong management team.


Price:
$136.440
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2017-06-14 PAST TOP PICK John O'Connell, CFA

(A Top Pick July 6/16. Up 16%.) Biotechnology company involved in cancer drugs. 20% earnings growth. Trading at 14X earnings. Strong balance sheet. Still a buy.


Price:
$121.040
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2017-06-02 PARTIAL BUY Brian Acker, CA

He likes this. It closed at $116.41, and his model price is $145.80, a 25% upside. Maybe this gets down to $97, which would be an absolute Buy. Buy half a position now, and when it went cheaper, Buy the other half.


Price:
$118.730
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH on US$
Owned:
Yes
2017-05-29 TOP PICK Teal Linde

They are growing nicely.  One of the fastest growing large cap pharma in North America.  Their slowest growth year was 14%.  Otherwise they averaged 20% per year over the last 10 years.  (Analysts’ target: $147) .


Price:
$116.780
Subject:
NORTH AMERICAN - LARGE/MID CAPS
Bias:
SELECTIVE
Owned:
Yes
2017-05-26 PAST TOP PICK Stan Wong

(A Top Pick April 6/16. Up 8%.) Their cancer drug continues to do well. They have a strong pipeline behind that. The shares are trading at 15X forward earnings, with what he expects to be a 20% long-term growth rate. That gives a PEG ratio of .75. Still very cheap.


Price:
$116.780
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
UNKNOWN
Owned:
Yes
2017-05-19 DON'T BUY John Petrides

Trading at 25X price to cash flow, a bit too rich for him. The stock is up 17% over the last 12 months. The bet on this company is that you have faith in their pipeline executing on future drugs. There is much more attractive value in healthcare outside of this.


Price:
$116.930
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
No
2017-05-10 PAST TOP PICK Paul Macdonald

(A Top Pick Feb 22/17. Up 14.45%.) One of the few companies that can double their revenue between now and 2020, without actually having pipeline success. Trading at 16X next year’s.


Price:
$119.680
Subject:
HEALTHCARE
Bias:
UNKNOWN
Owned:
Yes
2017-05-10 TOP PICK Paul Macdonald

They are able to double revenues between now and 2020 without a lot of pipeline success. The PEG ratio at .8, is not painful for a lot of their growth. Great financial metrics and you are not paying a lot for it. Some recent volatility presents a decent entry point. (Analysts’ price target is $146.)


Price:
$119.680
Subject:
HEALTHCARE
Bias:
UNKNOWN
Owned:
Yes
Showing 1 to 15 of 49 entries
<< < 1 2 3 4 > >>

No Comments.


You must be logged in to comment.